Current evidence on the diagnosis and management of immune checkpoint inhibitor associated myocarditis
Immune checkpoint inhibitor-associated myocarditis (ICI-M) is a rare but life-threatening immune-related adverse event. Reported mortality ranges from 27 to 50% in earlier cohorts, with a more recent pooled estimate of approximately 26% in systematic reviews incorporating 2021 to 2022 data. Incidence is approximately 1...